

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Currently Amended). A method for ~~preventing or~~ inhibiting neuronal secondary degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), or for protecting nerves from glutamate toxicity, which comprises administering to an individual in need thereof an amount of poly-Glu,Tyr effective to ~~prevent or inhibit~~ neuronal secondary degeneration, or to promote nerve regeneration, in the CNS or PNS, or to protect nerves from glutamate toxicity.

2 (Currently Amended). A method in accordance with claim 1, wherein the individual in need is one suffering from ~~for reducing secondary~~ neuronal degeneration caused by the neurodegenerative effects of an injury, disease, disorder or condition that has caused primary neuronal damage in the CNS or PNS of ~~the that individual, in need, which~~ and wherein said administering step comprises administering poly-Glu,Tyr in an amount effective to reduce the secondary neurodegeneration at the site.

3. (Original). A method in accordance with claim 2, wherein the individual in need is one suffering from an injury that has caused primary neuronal damage.

4 (Original). A method in accordance with claim 3, wherein said injury is selected from the group consisting of spinal cord injury, closed head injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke, cerebral ischemia, optic nerve injury, ~~myocardial infarction~~ and injury caused by tumor excision.

5 (Original). A method in accordance with claim 4, wherein said injury is spinal cord injury.

6 (Original). A method in accordance with claim 4, wherein said injury is ischemic stroke.

7 (Currently Amended). A method in accordance with claim 2, wherein said injury, disease, disorder or condition is a neurodegenerative disease, disorder or condition associated with the eye.

8. (Currently Amended). A method in accordance with claim 7, wherein said neurodegenerative-~~condition~~ disease, disorder or ~~disease~~ condition associated with the eye is non-arteritic optic neuropathy, ~~age-related macular degeneration,~~ ~~a retinal disorder~~ or a disease associated with elevated intraocular pressure.

9 (Cancelled).

10 (Currently Amended). A method in accordance with claim 1, wherein said individual in need is one having ~~for~~  
~~treating~~ an injury, disease, disorder or condition caused or exacerbated by glutamate toxicity, and wherein said  
administering step ~~which~~ comprises administering poly-Glu,Tyr to the individual in need in an amount effective to ameliorate the neurodegeneration caused or exacerbated by glutamate toxicity.

11 (Currently Amended). A method in accordance with claim 10, wherein said injury, disease, disorder or condition caused or exacerbated by glutamate toxicity is a neurodegenerative disease, disorder or condition.

12 (Currently Amended). A method in accordance with claim 11, wherein said neurodegenerative disease, disorder or condition is selected from the group consisting of a ~~Alzheimer's type~~ senile dementia, ~~a non-Alzheimer's type~~  
~~senile dementia,~~ Parkinson's disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS), ~~Alper's disease,~~ ~~Batten disease,~~ ~~Cockayne~~  
~~syndrome,~~ ~~Guillain-Barré syndrome,~~ ~~Lewy body disease,~~ and Creutzfeldt-Jakob disease.

13 (Currently Amended). A method in accordance with claim 10, wherein said injury, disease, disorder or condition

caused or exacerbated by glutamate toxicity is a peripheral neuropathy.

14 (Original). A method in accordance with claim 13, wherein said peripheral neuropathy is ~~a mononeuropathy or polyneuropathy~~ selected from the group consisting of adrenomyeloneuropathy, ~~alcoholic neuropathy,~~ amyloid neuropathy ~~or polyneuropathy,~~ axonal neuropathy, chronic sensory ataxic neuropathy ~~associated with Sjogren's syndrome,~~ diabetic neuropathy, ~~an entrapment neuropathy nerve compression syndrome,~~ carpal tunnel syndrome, ~~a nerve root compression that may follow cervical or lumbar intervertebral disc herniation,~~ giant axonal neuropathy, ~~hepatic neuropathy, ischemic ischemia, neuropathy, nutritional polyneuropathy due to~~ vitamin deficiency, malabsorption syndromes, ~~or alcoholism, porphyric polyneuropathy,~~ a toxic neuropathy caused by organophosphates, ~~uremic polyneuropathy,~~ a neuropathy associated with a disease or disorder selected from the group consisting of ~~acromegaly,~~ ataxia telangiectasia, Charcot-Marie-Tooth disease, ~~chronic obstructive pulmonary lung~~ diseases, Fabry's disease, Friedreich ataxia, ~~Guillain-Barré syndrome,~~ hypoglycemia, IgG or IgA monoclonal gammopathy ~~(non-malignant or associated with multiple myeloma or with osteosclerotic myeloma)~~ gammopathies, lipoproteinemia, ~~polycythemia vera,~~ Refsum's syndrome, ~~Reye's syndrome,~~ and

Sjogren-Larsson syndrome, or a polyneuropathy associated with various drugs, or with hypoglycemia, ~~with infections such as HIV infection, or with cancer.~~

15 (Currently Amended). A method in accordance with claim 10, wherein said injury, disease, disorder or condition caused or exacerbated by glutamate toxicity is ~~for treatment of~~ epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, or opiate tolerance and dependence.

16 (Currently Amended). A method in accordance with claim 1, wherein the individual in need is one having ~~for the treatment of~~ a psychosis or psychiatric disorder selected from the group consisting of an anxiety disorder, a mood disorder, schizophrenia or a schizophrenia-related disorder, drug use and dependence and withdrawal, and a memory loss or cognitive disorder.

17 (Currently Amended). A method in accordance with claim 16 wherein said psychosis or psychiatric disorder is an anxiety disorder ~~is~~ selected from the group consisting of a phobic disorder, an obsessive-compulsive disorder, a post-traumatic stress disorder, an acute stress disorder and a generalized anxiety disorder; said mood disorder is selected from the group consisting of depression, a dysthymic disorder, a bipolar disorder and a cyclothymic disorder; said

schizophrenia-related disorder is selected from the group consisting of brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; said drug use and dependence is selected from the group consisting of alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and said memory loss disorder is amnesia or memory loss associated with a disease or disorder selected from the group consisting of Alzheimer's type dementia, non-Alzheimer's type dementia, Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

18 (Currently Amended). A method in accordance with claim ~~17~~16, wherein said psychosis or psychiatric disorder is ~~for treatment of schizophrenia.~~

19 - 20 (Canceled).

21 (Original). A method for down-regulation of the suppressive activity of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells (Treg) on CD4<sup>+</sup>CD25<sup>-</sup> effector T cells (Teff) in an individual suffering from a neurological or neurodegenerative injury, condition, disorder or disease, which comprises administering to said individual in need an amount of the copolymer poly-Glu,Tyr effective for the treatment of said neurological or neurodegenerative injury, condition, disorder or disease.

22 (Currently Amended). A method in accordance with claim 21, wherein the individual in need is one suffering from secondary neuronal degeneration injury caused by a primary neuronal injury, and wherein said administering step comprises administering poly-Glu,Tyr ~~is administered to said that~~ individual ~~in need~~ in an amount effective for reducing neuronal degeneration caused by said primary neuronal injury.

23 (Currently Amended). A method in accordance with claim 22, wherein said primary neuronal injury is selected from the group consisting of spinal cord injury, closed head injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke, cerebral ischemia, optic nerve injury, ~~myocardial infarction~~ and injury caused by tumor excision.

24 (Currently Amended). A method in accordance with claim 23, wherein said primary neuronal injury is spinal cord injury.

25 (Currently Amended). A method in accordance with claim 23 wherein said primary neuronal injury is ischemic stroke.

26 (Currently Amended). A method in accordance with claim 21, wherein said individual in need is one suffering from ~~for treating~~ an injury, disease, disorder or condition caused or exacerbated by glutamate toxicity, and wherein said administering step ~~which~~ comprises administering poly-Glu,Tyr

to ~~the~~ that individual ~~in need~~ in an amount effective to ameliorate the neurodegeneration caused or exacerbated by glutamate toxicity.

27 (Currently Amended). A method in accordance with claim 26, wherein said injury, disease, disorder or condition is a neurodegenerative disease, disorder or condition associated with the eye.

28 (Currently Amended). A method in accordance with claim 27, wherein said neurodegenerative ~~condition~~ disease, disorder or ~~disease~~ condition associated with the eye is non-arteritic optic neuropathy, ~~age-related macular degeneration,~~ ~~a retinal disorder~~ or a disease associated with elevated intraocular pressure.

29 (Cancelled).

30 (Currently Amended). A method in accordance with claim 26, wherein said injury, disease, disorder or condition caused or exacerbated by glutamate toxicity is a neurodegenerative disease, disorder or condition.

31 (Currently Amended). A method in accordance with claim 30, wherein said neurodegenerative disease, disorder or condition ~~caused or exacerbated by glutamate toxicity~~ is a ~~neurodegenerative disease~~ selected from the group consisting of ~~a Alzheimer's type~~ senile dementia, ~~a non-Alzheimer's type~~ ~~senile dementia,~~ Parkinson's disease, facial nerve (Bell's)



palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS), ~~Alper's disease, Batten disease, Cockayne syndrome, Lewy body disease, Guillain-Barré syndrome, and~~ Creutzfeldt-Jakob disease.

32 (Currently Amended). A method in accordance with claim 26, wherein said injury, disease, disorder or condition caused or exacerbated by glutamate toxicity is a peripheral neuropathy.

33 (Original). A method in accordance with claim 32, wherein said peripheral neuropathy is ~~a mononeuropathy or polyneuropathy~~ selected from the group consisting of adrenomyeloneuropathy, ~~alcoholic neuropathy, amyloid neuropathy or polyneuropathy, axonal neuropathy, chronic sensory ataxic neuropathy associated with Sjogren's syndrome, diabetic neuropathy, an entrapment neuropathy nerve compression syndrome such as carpal tunnel syndrome, or a nerve root compression that may follow cervical or lumbar intervertebral disc herniation, giant axonal neuropathy, hepatic neuropathy, ischemic neuropathy, nutritional polyneuropathy due to ischemia, vitamin deficiency, malabsorption syndromes, or alcoholism, porphyric polyneuropathy, a toxic neuropathy caused by organophosphates, uremic polyneuropathy, a neuropathy associated with a disease or disorder selected from the group consisting of acromegaly,~~

ataxia telangiectasia, Charcot-Marie-Tooth disease, ~~chronic~~  
obstructive ~~pulmonary-lung~~ diseases, Fabry's disease,  
Friedreich ataxia, ~~Guillain-Barré syndrome~~, hypoglycemia, IgG  
or IgA monoclonal gammopathy ~~(non-malignant or associated with~~  
~~multiple myeloma or with osteosclerotic myeloma)~~ gammopathies,  
lipoproteinemia, ~~polycythemia vera~~, Refsum's syndrome, ~~Reye's~~  
~~syndrome~~, and Sjogren-Larsson syndrome, or a polyneuropathy  
associated with various drugs, or with hypoglycemia, ~~with~~  
~~infections such as HIV infection, or with cancer.~~

34 (Currently Amended). A method in accordance with  
claim 21, wherein the individual in need is one suffering from  
~~for treatment of~~ epilepsy, amnesia, anxiety, hyperalgesia,  
psychosis, seizures, oxidative stress, or opiate tolerance and  
dependence.

35 (Currently Amended). A method in accordance with  
claim 21, wherein the individual in need is one suffering from  
~~for the treatment of~~ a psychosis or psychiatric disorder  
selected from the group consisting of an anxiety disorder, a  
mood disorder, schizophrenia or a schizophrenia-related  
disorder, drug use and dependence and withdrawal, and a memory  
loss or cognitive disorder.

36 (Currently Amended). A method in accordance with  
claim 35, wherein said psychosis or psychiatric disorder is an  
anxiety disorder ~~is~~ selected from the group consisting of a

phobic disorder, an obsessive-compulsive disorder, a post-traumatic stress disorder, an acute stress disorder and a generalized anxiety disorder; said mood disorder is selected from the group consisting of depression, a dysthymic disorder, a bipolar disorder and a cyclothymic disorder; said schizophrenia-related disorder is selected from the group consisting of brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; said drug use and dependence is selected from the group consisting of alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and said memory loss disorder is amnesia or memory loss associated with a disease or disorder selected from the group consisting of Alzheimer's type dementia, non-Alzheimer's type dementia, Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

37 (Currently Amended). A method in accordance with claim-~~36~~35, wherein said psychosis or psychiatric disorder is  
for treatment of schizophrenia.

38 - 39 (Canceled).

40 (Original). A method for conferring neuroprotection to an individual suffering from a neurological injury, which comprises administering poly-Glu,Tyr to the

individual in need in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

41 (Original). A method in accordance with claim 40, wherein said neurological injury is a neuronal degeneration caused by acute or chronic injury.

42 (Currently Amended). A method in accordance with claim 41, wherein said acute or chronic injury is selected from the group consisting of spinal cord injury, closed head injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke, cerebral ischemia, optic nerve injury, ~~myocardial infarction~~ and injury caused by tumor excision.

43 (Currently Amended). A method in accordance with claim ~~4~~ 42, wherein said acute or chronic injury is spinal cord injury.

44 (Currently Amended). A method in accordance with claim 42, wherein said acute or chronic injury is ischemic stroke.

45 (Original). A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease, disorder or condition, which comprises administering poly-Glu,Tyr to the individual in need in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease, disorder or condition.

46 (Currently Amended). A method in accordance with claim 45, wherein said neurological or neurodegenerative disease, disorder or condition is a disease, disorder or condition caused or exacerbated by glutamate toxicity.

47 (Currently Amended). A method in accordance with claim 46, wherein said ~~neurodegenerative condition~~disease, disorder or ~~disease~~ condition caused or exacerbated by glutamate toxicity is associated with the eye.

48 (Currently Amended). A method in accordance with claim 47, wherein said ~~neurodegenerative condition~~ disease, disorder or ~~disease~~ condition associated with the eye is non-arteritic optic neuropathy, ~~age-related macular degeneration, a retinal disorder~~ or a disease associated with elevated intraocular pressure.

49 (Cancelled).

50 (Currently Amended). A method in accordance with claim 45, wherein said neurological or neurodegenerative condition, ~~or~~ disease, or disorder or condition is selected from the group consisting of ~~Alzheimer-type senile dementia, non-Alzheimer-type senile dementia,~~ Parkinson's disease, facial nerve (Bell's) palsy, Huntington's chorea, amyotrophic lateral sclerosis, and a prion disease including Creutzfeldt-Jakob disease, ~~Alper's disease, Batten disease, Cockayne syndrome, Guillain-Barré syndrome, and Lewy body disease.~~

51 (Currently Amended). A method in accordance with claim 45, wherein said neurological or neurodegenerative condition disease, disorder or ~~disease-condition~~ is a peripheral neuropathy.

52 (Original). A method in accordance with claim 51, wherein said peripheral neuropathy is ~~a mononeuropathy or polyneuropathy~~ selected from the group consisting of adrenomyeloneuropathy, ~~alcoholic neuropathy,~~ amyloid ~~neuropathy or polyneuropathy,~~ axonal neuropathy, chronic sensory ataxic neuropathy, ~~associated with Sjogren's syndrome,~~ diabetic neuropathy, ~~an entrapment neuropathy nerve compression syndrome such as carpal tunnel syndrome, or a nerve root compression that may follow cervical or lumbar intervertebral disc herniation,~~ giant axonal neuropathy, ~~hepatic neuropathy, ischemic neuropathy, nutritional polyneuropathy due to ischemia,~~ vitamin deficiency, malabsorption syndromes, ~~or alcoholism, porphyric polyneuropathy,~~ a toxic neuropathy caused by organophosphates, ~~uremic polyneuropathy,~~ a neuropathy associated with a disease or disorder selected from the group consisting of ~~acromegaly,~~ ataxia telangiectasia, Charcot-Marie-Tooth disease, ~~chronic~~ obstructive ~~pulmonary lung~~ diseases, Fabry's disease, Friedreich ataxia, ~~Guillain-Barré syndrome,~~ hypoglycemia, IgG or IgA ~~monoclonal gammopathy (non-malignant or associated with~~

~~multiple myeloma or with osteosclerotic myeloma)~~gammopathies,  
lipoproteinemia, ~~polycythemia vera~~, Refsum's syndrome, ~~Reye's~~  
~~syndrome~~, and Sjogren-Larsson syndrome, or a polyneuropathy  
associated with various drugs, or with hypoglycemia, ~~with~~  
~~infections such as HIV infection, or with cancer.~~

53 (Currently Amended). A method for conferring  
neuroprotection to an individual suffering from a neurological  
or neurodegenerative disease, disorder or condition -selected  
from the group consisting of epilepsy, amnesia, anxiety,  
hyperalgesia, psychosis or psychiatric disorder, seizures,  
oxidative stress, or opiate tolerance and dependence, which  
comprises administering poly-Glu,Tyr to the individual in need  
in an amount effective to ameliorate said neurological or  
neurodegenerative disease, disorder or condition in said  
individual.

54 (Currently Amended). A method in accordance with  
claim 53, wherein said neurological or neurodegenerative  
~~condition~~ disease, disorder or ~~disease~~ condition is a  
psychosis or psychiatric disorder selected from the group  
consisting of an anxiety disorder, a mood disorder,  
schizophrenia or a schizophrenia-related disorder, drug use  
and dependence and withdrawal, and a memory loss or cognitive  
disorder.

55 (Currently Amended). A method in accordance with claim 54, wherein said psychosis or psychiatric disorder is an anxiety disorder ~~is~~ selected from the group consisting of a phobic disorder, an obsessive-compulsive disorder, a post-traumatic stress disorder, an acute stress disorder and a generalized anxiety disorder; said mood disorder is selected from the group consisting of depression, a dysthymic disorder, a bipolar disorder and a cyclothymic disorder; said schizophrenia-related disorder is selected from the group consisting of brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; said drug use and dependence is selected from the group consisting of alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and said memory loss disorder is amnesia or memory loss associated with a disease or disorder selected from the group consisting of Alzheimer's type dementia, non-Alzheimer's type dementia, Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

56 (Currently Amended). A method in accordance with claim ~~55-54~~, wherein said psychosis or psychiatric disorder is ~~for treatment of schizophrenia.~~

57 (Canceled).



Appln. No. 10/807,414  
Amdt. dated November 1, 2006  
Reply to Office action of June 6, 2006

58 (Currently Amended). A method in accordance with  
claim ~~57~~72, wherein said neurotoxin is an organophosphate  
nerve gas.

59-71 (Cancelled).

72 (New). A method for protecting nerves from the  
effects of exposure to a neurotoxin, comprising administering  
to an individual who has been exposed or is subject to  
exposure to a neurotoxin an amount of poly-Glu,Tyr effective  
to protect the nerves of said individual from the effects of  
exposure to a neurotoxin.